Table 3.
Effect of polymyxin B in different duration, dose and medication mod on curative effect
| Group | n | Effective rate (n (%)) | Clearance rate (n (%)) |
|---|---|---|---|
| Duration of treatment ( days) | |||
| 3–7 | 71 | 16 (16.8%) | 12 (16.9%) |
| 8–14 | 57 | 35 (61.4%)a | 32 (56.1%)a |
| > 14 | 53 | 39 (73.5%)a | 32 (60.4%)a |
| Daily dose (mg/kg/day) | |||
| 1.5 | 70 | 19 (27.1%) | 25 (35.7%) |
| 2.0 | 97 | 46 (47.4%)b | 53 (54.6%)b |
| 2.5 | 14 | 10 (71.4%)b | 11 (78.6%)b |
| Medication mode | |||
| Polymyxin B monotherapy | 14 | 3 (28.57%) | 2 (14.29%) |
| Polymyxin B combination | 167 | 87 (52.1%)c | 74 (44.3%)c |
| Carbapenems | 39 | 20 (51.3%) | 15 (38.5%)d |
| Tigecycline | 61 | 15 (48.4%) | 12 (38.7%)d |
| Fosfomycin | 18 | 10 (55.6%) | 9 (50.0%)d |
| Tigecycline + fosfomycin | 30 | 19 (63.3%) | 20 (66.7%) |
| Carbapenems + tigecycline | 17 | 10 (58.8%) | 8 (52.9%)d |
| Other | 32 | 13 (41.9%) | 10 (31.3%)d |
In the group of treatment duration, compared with 3–7 days group, aP < 0.05
In the group of daily dose, compared with 1.5 mg/kg/days group, bP < 0.05
In the group of medication mode, compared with polymyxin B monotherapy group, cP < 0.05; compared with polymyxin + tigecycline + fosfomycin group, dP < 0.05